Benzinga | Mar 10, 2021 04:01PM EST

Lantern Pharma Q4 EPS $(0.47) Misses $(0.45) Estimate; Says Had Cash And Equivalents Of $19.2M As Of Dec. 31

Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.45) by 4.44 percent.